A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir

Oral direct-acting antivirals (DAAs) are the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the first agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b. More recently, ombitasvir/paritaprevir/ritonavir is also recommend...

Full description

Bibliographic Details
Main Authors: Kazuo Tarao, Kouzo Yamada
Format: Article
Language:English
Published: Karger Publishers 2017-06-01
Series:Case Reports in Gastroenterology
Subjects:
Online Access:http://prod.karger.com/Article/FullText/462965
_version_ 1818854352505274368
author Kazuo Tarao
Kouzo Yamada
author_facet Kazuo Tarao
Kouzo Yamada
author_sort Kazuo Tarao
collection DOAJ
description Oral direct-acting antivirals (DAAs) are the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the first agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b. More recently, ombitasvir/paritaprevir/ritonavir is also recommended as a potent therapy for HCV genotype 1b. Among the adverse events associated with these oral DAAs, interstitial pneumonia is one of the most severe ones. Regarding treatment with daclatasvir plus asunaprevir or sofosbuvir plus ledipasvir, a few cases have already been reported in a postmarketing surveillance. Recently, we have encountered a HCV-associated genotype 1b cirrhosis patient who developed interstitial pneumonia during treatment with ombitasvir/paritaprevir/ritonavir and who recovered after drug discontinuation without corticosteroid therapy. Interstitial pneumonia was confirmed by chest x-ray and chest computed tomography. The serum KL-6 level was elevated to 1,180 U/mL. The total duration of the drug administration was 7 weeks, and she achieved SVR24. This is the first detailed report in the literature on the development of interstitial pneumonia during treatment with ombitasvir/paritaprevir/ritonavir. When dry cough appeared in the treatment with DAAs, chest computed tomography and the evaluation of serum KL-6 level were recommended.
first_indexed 2024-12-19T07:51:21Z
format Article
id doaj.art-0c99429b362d466ba24a6264ddc7a3b8
institution Directory Open Access Journal
issn 1662-0631
language English
last_indexed 2024-12-19T07:51:21Z
publishDate 2017-06-01
publisher Karger Publishers
record_format Article
series Case Reports in Gastroenterology
spelling doaj.art-0c99429b362d466ba24a6264ddc7a3b82022-12-21T20:30:08ZengKarger PublishersCase Reports in Gastroenterology1662-06312017-06-0111236937610.1159/000462965462965A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/RitonavirKazuo TaraoKouzo YamadaOral direct-acting antivirals (DAAs) are the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the first agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b. More recently, ombitasvir/paritaprevir/ritonavir is also recommended as a potent therapy for HCV genotype 1b. Among the adverse events associated with these oral DAAs, interstitial pneumonia is one of the most severe ones. Regarding treatment with daclatasvir plus asunaprevir or sofosbuvir plus ledipasvir, a few cases have already been reported in a postmarketing surveillance. Recently, we have encountered a HCV-associated genotype 1b cirrhosis patient who developed interstitial pneumonia during treatment with ombitasvir/paritaprevir/ritonavir and who recovered after drug discontinuation without corticosteroid therapy. Interstitial pneumonia was confirmed by chest x-ray and chest computed tomography. The serum KL-6 level was elevated to 1,180 U/mL. The total duration of the drug administration was 7 weeks, and she achieved SVR24. This is the first detailed report in the literature on the development of interstitial pneumonia during treatment with ombitasvir/paritaprevir/ritonavir. When dry cough appeared in the treatment with DAAs, chest computed tomography and the evaluation of serum KL-6 level were recommended.http://prod.karger.com/Article/FullText/462965Interstitial pneumoniaDirect-acting antiviralsDry coughHepatitis C virus liver diseaseOmbitasvir/paritaprevir/ritonavir
spellingShingle Kazuo Tarao
Kouzo Yamada
A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir
Case Reports in Gastroenterology
Interstitial pneumonia
Direct-acting antivirals
Dry cough
Hepatitis C virus liver disease
Ombitasvir/paritaprevir/ritonavir
title A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir
title_full A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir
title_fullStr A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir
title_full_unstemmed A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir
title_short A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir
title_sort hepatitis c virus associated cirrhotic patient developing interstitial pneumonia during the course of antiviral therapy with ombitasvir paritaprevir ritonavir
topic Interstitial pneumonia
Direct-acting antivirals
Dry cough
Hepatitis C virus liver disease
Ombitasvir/paritaprevir/ritonavir
url http://prod.karger.com/Article/FullText/462965
work_keys_str_mv AT kazuotarao ahepatitiscvirusassociatedcirrhoticpatientdevelopinginterstitialpneumoniaduringthecourseofantiviraltherapywithombitasvirparitaprevirritonavir
AT kouzoyamada ahepatitiscvirusassociatedcirrhoticpatientdevelopinginterstitialpneumoniaduringthecourseofantiviraltherapywithombitasvirparitaprevirritonavir
AT kazuotarao hepatitiscvirusassociatedcirrhoticpatientdevelopinginterstitialpneumoniaduringthecourseofantiviraltherapywithombitasvirparitaprevirritonavir
AT kouzoyamada hepatitiscvirusassociatedcirrhoticpatientdevelopinginterstitialpneumoniaduringthecourseofantiviraltherapywithombitasvirparitaprevirritonavir